Geron Corporation (GERN) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $0.89 (-6.28%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 27, 2025 | Peter Lawson | Barclays | $4.00 | +351.1% |
| Nov 5, 2024 | Emily Bodnar | H.C. Wainwright | $8.00 | +802.2% |
| Oct 22, 2024 | Kalpit Patel | B.Riley Financial | $5.50 | +520.2% |
| Sep 9, 2024 | Faisal Khurshid | Leerink Partners | $7.00 | +689.4% |
| Jun 10, 2024 | Corinne Jenkins | Goldman Sachs | $6.00 | +576.6% |
| Jun 10, 2024 | Stephen Willey | Stifel Nicolaus | $7.00 | +689.4% |
| Apr 30, 2024 | Joel Beatty | Robert W. Baird | $4.50 | +407.5% |
| Mar 15, 2024 | Gil Blum | Needham | $5.00 | +463.9% |
| Mar 15, 2024 | Corinne Jenkins | Goldman Sachs | $5.00 | +463.9% |
Top Analysts Covering GERN
GERN vs Sector & Market
| Metric | GERN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.41 |
| Analyst Count | 2 | 8 | 19 |
| Target Upside | +564.2% | +153002.0% | +21.5% |
| P/E Ratio | -11.74 | 3.48 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $65M | $66M | $67M | 3 |
| 2027-03-31 | $70M | $72M | $73M | 3 |
| 2027-06-30 | $77M | $78M | $80M | 2 |
| 2027-09-30 | $83M | $85M | $86M | 2 |
| 2027-12-31 | $89M | $91M | $93M | 3 |
| 2028-12-31 | $449M | $481M | $545M | 5 |
| 2029-12-31 | $641M | $687M | $778M | 2 |
| 2030-12-31 | $852M | $914M | $1.03B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.00 | $-0.00 | $-0.00 | 1 |
| 2027-03-31 | $0.01 | $0.01 | $0.01 | 1 |
| 2027-06-30 | $0.02 | $0.02 | $0.02 | 1 |
| 2027-09-30 | $0.02 | $0.02 | $0.02 | 1 |
| 2027-12-31 | $0.03 | $0.03 | $0.03 | 1 |
| 2028-12-31 | $-0.06 | $0.16 | $0.60 | 5 |
| 2029-12-31 | $0.38 | $0.42 | $0.49 | 1 |
| 2030-12-31 | $0.58 | $0.64 | $0.74 | 1 |
Frequently Asked Questions
What is the analyst consensus for GERN?
The consensus among 2 analysts covering Geron Corporation (GERN) is Buy with an average price target of $5.89.
What is the highest price target for GERN?
The highest price target for GERN is $8.00, set by Emily Bodnar at H.C. Wainwright on 2024-11-05.
What is the lowest price target for GERN?
The lowest price target for GERN is $4.00, set by Peter Lawson at Barclays on 2025-02-27.
How many analysts cover GERN?
2 analysts have issued ratings for Geron Corporation in the past 12 months.
Is GERN a buy or sell right now?
Based on 2 analyst ratings, GERN has a consensus rating of Buy (2.00/5) with a +564.2% upside to the consensus target of $5.89.
What are the earnings estimates for GERN?
Analysts estimate GERN will report EPS of $-0.00 for the period ending 2026-12-31, with revenue estimated at $66M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.